Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

NC Quantum Apex PTCA Dilatation Balloon Catheter receives CE Mark and FDA approval

Boston Scientific Corporation today announced CE Mark and U.S. Food and Drug Administration approval of its NC Quantum Apex PTCA Dilatation Balloon Catheter. The Company plans to launch the product in European markets this week and in the U.S. next month.

25 May 2010

Blood biomarker underscores role of inflammation in vascular disease

UC Davis researchers have discovered that a blood component linked with inflammation can predict coronary artery disease in African-Americans.

21 May 2010

Significant proportion of men with ED exhibit early signs of CAD: Review

International experts are calling for all men experiencing impotence to undergo thorough medical assessments, after an extensive review showed that a significant proportion of men with erectile dysfunction exhibit early signs of coronary artery disease.

19 May 2010

Study reveals association between depression and coronary spasm

A study published in the current issue of Psychotherapy and Psychosomatics explores the relationship between depression and coronary artery spasm.

18 May 2010

Apnex HGNS System shows promising results in people suffering from OSA

Apnex Medical announced today that preliminary data from a first-in-man clinical study showed significant improvements in sleep for people suffering from obstructive sleep apnea. The Apnex HGNS™ System, developed by the St. Paul-based company, is a device designed to treat OSA, which is a serious life-threatening illness characterized by fragmented sleep and excessive day-time sleepiness.

18 May 2010

SPIROCOR's RSR non-invasively measures presence of significant coronary artery disease

Newly published data confirm a non-invasive Respiratory Stress Response (RSR) can quickly and accurately measure the presence of significant coronary artery disease (sCAD), the leading cause of cardiovascular death worldwide. Patients in the study with sCAD had a lower RSR compared to patients without.

14 May 2010

GE Healthymagination Fund invests $5M in CardioDx

GE Healthcare, the healthcare business of GE and CardioDx, a pioneer in cardiovascular genomic diagnostics, announced today that the companies have entered into a strategic alliance to advance and co-develop diagnostic technologies to improve the care and management of patients with cardiovascular disease.

14 May 2010

Stereotaxis to be featured prominently in 31st HRS

Stereotaxis' safety and efficacy in the treatment of patients with complex arrhythmias such as atrial fibrillation, ventricular tachycardia, and congenital heart defects will be featured prominently in the scientific program of the 31st Annual Heart Rhythm Scientific Sessions in Denver, Colorado. Eight podium presentations and eight posters will underscore the broad clinical leadership that Stereotaxis has achieved in the treatment of patients with complex cardiac arrhythmias.

13 May 2010

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

Regeneron Pharmaceuticals, Inc. (REGN) provided an update on two antibody product candidates in its pipeline and scheduled its first Investor Day to be held in New York City on July 15, 2010. Both product candidates, REGN727 (SAR236553) and, REGN475 (SAR164877) are being developed with sanofi-aventis under a global, strategic collaboration to discover, develop, and commercialize fully human antibodies.

13 May 2010

Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule

Resverlogix is pleased to announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a small molecule therapy for the treatment of atherosclerosis has now completed dosing. "The completion of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and without any alterations to the dose levels of the three drug receiving cohorts, is another major step forward in the development of this important cardiovascular drug.

13 May 2010

BSX receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Boston Scientific Corporation today announced it has received CE Mark approval for its TAXUS Element Paclitaxel-Eluting Coronary Stent System, the Company's third-generation drug-eluting stent technology. This approval includes a specific indication for the treatment of diabetic patients.

13 May 2010

Boston Scientific receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Angiotech Pharmaceuticals, Inc. today announced that its corporate partner, Boston Scientific Corporation, has received CE Mark approval for its TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System, Boston Scientific's third-generation drug-eluting stent (DES) technology.

13 May 2010

Stereotaxis launches Vdrive module for remote manipulation of diagnostic devices during EP procedures

Stereotaxis, Inc. today announces the introduction of its new Vdrive™, an expansion of its Magnetic Navigation platform that facilitates remote manipulation of diagnostic devices used during electrophysiology (EP) procedures. The company is planning to preview the Vdrive at the HRS meeting this week, and will be commercially available when regulatory processes are complete.

12 May 2010

CHD mortality rate in Ontario decreased by 35%: Study

From 1994 to 2005 in Ontario, Canada, there was a 35 percent decrease in the rate of deaths from coronary heart disease, with about half of this reduction associated with improvements in traditional CHD risk factors such as total cholesterol levels and systolic blood pressure, according to a study in the May 12 issue of JAMA.

12 May 2010

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis announced today the initiation of a multinational, randomized double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10, 000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.

12 May 2010

Challenges faced in cardiac imaging

When patients present with chest pain or other high-risk symptoms of heart problems, doctors increasingly rely on nuclear imaging and computed tomography (CT) tests to find out whether there is evidence of heart disease, blockages in the coronary arteries or reduced blood flow to the heart. Results of these procedures can help guide life-saving prevention and treatment options.

11 May 2010

Exposure to fine particulate matter can trigger cardiovascular deaths, heart attacks

The scientific evidence linking air pollution to heart attacks, strokes and cardiovascular death has "substantially strengthened," and people, particularly those at high cardiovascular risk, should limit their exposure, according to an updated American Heart Association scientific statement.

11 May 2010

Stereotaxis reports $10.6 million revenue for first-quarter 2010

Stereotaxis, Inc. today reported financial results for the first quarter ended March 31, 2010 highlighted by recurring revenue and gross margin achieving record levels while operating losses continued to decline. In addition, the Company reported that its efforts to drive clinical adoption within the U.S. market are favorably impacting utilization rates.

6 May 2010

Abbott's SPIRIT IV trial results published in The New England Journal of Medicine

Findings from Abbott's SPIRIT IV trial, one of the largest randomized clinical trials comparing two drug eluting stents, with 3,690 U.S.-based patients, were published today in The New England Journal of Medicine.

6 May 2010

CSI fiscal third-quarter revenue increases 9% to $16.5 million

Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal third quarter ended March 31, 2010.

6 May 2010

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

NC Quantum Apex PTCA Dilatation Balloon Catheter receives CE Mark and FDA approval

Blood biomarker underscores role of inflammation in vascular disease

Significant proportion of men with ED exhibit early signs of CAD: Review

Study reveals association between depression and coronary spasm

Apnex HGNS System shows promising results in people suffering from OSA

SPIROCOR's RSR non-invasively measures presence of significant coronary artery disease

GE Healthymagination Fund invests $5M in CardioDx

Stereotaxis to be featured prominently in 31st HRS

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule

BSX receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Boston Scientific receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Stereotaxis launches Vdrive module for remote manipulation of diagnostic devices during EP procedures

CHD mortality rate in Ontario decreased by 35%: Study

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Challenges faced in cardiac imaging

Exposure to fine particulate matter can trigger cardiovascular deaths, heart attacks

Stereotaxis reports $10.6 million revenue for first-quarter 2010

Abbott's SPIRIT IV trial results published in The New England Journal of Medicine

CSI fiscal third-quarter revenue increases 9% to $16.5 million

Mastering RNA extraction for plant and fungal research – eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Mastering RNA extraction for plant and fungal research – eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in